{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:16:18Z","timestamp":1740122178821,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10620-023-08062-5","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:02:31Z","timestamp":1691578951000},"page":"4001-4008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An Assessment of Comparative Medication Durability in Inflammatory Bowel Disease Patients With and Without Co-morbid Psoriasis, Rheumatoid Arthritis, and\/or Enteropathic Arthritis"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-280X","authenticated-orcid":false,"given":"Kelly","family":"Cushing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Speliotes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D. R.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"8062_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/ecco-jcc\/jjy166","volume":"13","author":"S Bar Yehuda","year":"2019","unstructured":"Bar Yehuda S, Axlerod R, Toker O et al. The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN. Journal of Crohn\u2019s & colitis. 2019;13:324\u2013329. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy166.","journal-title":"Journal of Crohn's & colitis."},{"key":"8062_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2133.1982.tb01731.x","volume":"106","author":"VM Yates","year":"1982","unstructured":"Yates VM, Watkinson G, Kelman A. Further evidence for an association between psoriasis, Crohn\u2019s disease and ulcerative colitis. Br J Dermatol. 1982;106:323\u2013330. https:\/\/doi.org\/10.1111\/j.1365-2133.1982.tb01731.x.","journal-title":"Br J Dermatol."},{"key":"8062_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","volume":"129","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827\u2013836. https:\/\/doi.org\/10.1053\/j.gastro.2005.06.021.","journal-title":"Gastroenterology."},{"key":"8062_CR4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","volume":"102","author":"X Weng","year":"2007","unstructured":"Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern california-managed care organization. The American journal of gastroenterology. 2007;102:1429\u20131435. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01215.x.","journal-title":"The American journal of gastroenterology."},{"key":"8062_CR5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000514030","volume":"237","author":"JM Moon","year":"2021","unstructured":"Moon JM, Lee JY, Koh SJ et al. Incidence of Psoriasis in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Matched Cohort Study. Dermatology. 2021;237:330\u2013337. https:\/\/doi.org\/10.1159\/000514030.","journal-title":"Dermatology."},{"key":"8062_CR6","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","volume":"90","author":"D Ellinghaus","year":"2012","unstructured":"Ellinghaus D, Ellinghaus E, Nair RP et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636\u2013647. https:\/\/doi.org\/10.1016\/j.ajhg.2012.02.020.","journal-title":"Am J Hum Genet."},{"key":"8062_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu JZ, van Sommeren S, Huang H et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature genetics. 2015;47:979\u2013986. https:\/\/doi.org\/10.1038\/ng.3359.","journal-title":"Nature genetics."},{"key":"8062_CR8","doi-asserted-by":"publisher","unstructured":"Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature genetics. 2011\/03\/01 2011;43:246\u2013252. doi:https:\/\/doi.org\/10.1038\/ng.764","DOI":"10.1038\/ng.764"},{"key":"8062_CR9","doi-asserted-by":"crossref","unstructured":"Piruzian ES, Ishkin AA, Nikol'skaia TA, Abdeev RM, Bruskin SA. [The comparative analysis of psoriasis and Crohn disease molecular-genetical processes under pathological conditions]. Mol Biol (Mosk). Jan-Feb 2009;43:175\u20139.","DOI":"10.1134\/S002689330901021X"},{"key":"8062_CR10","doi-asserted-by":"publisher","unstructured":"Xi L, Garcet S, Ye Z, et al. A shared tissue transcriptome signature and pathways in psoriasis and ulcerative colitis. Sci Rep. Nov 17 2022;12:19740. doi:https:\/\/doi.org\/10.1038\/s41598-022-22465-w","DOI":"10.1038\/s41598-022-22465-w"},{"key":"8062_CR11","doi-asserted-by":"publisher","unstructured":"Devaprasad A, Radstake T, Pandit A. Integration of Immunome With Disease-Gene Network Reveals Common Cellular Mechanisms Between IMIDs and Drug Repurposing Strategies. Front Immunol. 2021;12:669400. doi:https:\/\/doi.org\/10.3389\/fimmu.2021.669400","DOI":"10.3389\/fimmu.2021.669400"},{"key":"8062_CR12","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/gut.2009.199679","volume":"60","author":"CW Lees","year":"2011","unstructured":"Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739\u20131753. https:\/\/doi.org\/10.1136\/gut.2009.199679.","journal-title":"Gut."},{"key":"8062_CR13","unstructured":"RStudio Team (2016). RStudio: Integrated Development for R. RStudio I, Boston, MA URL http:\/\/www.rstudio.com\/."},{"key":"8062_CR14","doi-asserted-by":"crossref","unstructured":"Wickham H, Averick M, Bryan J, al e. Welcome to the Tidyverse. Journal of Open Source Software. 2019;4:1686.","DOI":"10.21105\/joss.01686"},{"key":"8062_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","volume":"13","author":"DWK Sjoberg","year":"2021","unstructured":"Sjoberg DWK, Curry M et al. Reproducible Summary Tables with the gtsummary Package. The R Journal. 2021;13:570\u2013580.","journal-title":"The R Journal."},{"key":"8062_CR16","unstructured":"Kassambara A. ggpubr: 'ggplot2' Based Publication Ready Plots. 2020;R package version 0.4.0. https:\/\/CRAN.R-project.org\/package=ggpubr"},{"key":"8062_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000529080","volume":"15","author":"H Terui","year":"2023","unstructured":"Terui H, Moroi R, Masamune A, Aiba S, Yamasaki K. Possible Efficacy of Vedolizumab, an Anti-\u03b14\u03b27 Integrin Antibody Palmoplantar Pustulosis. Case Rep Dermatol. 2023;15:22\u201325. https:\/\/doi.org\/10.1159\/000529080.","journal-title":"Case Rep Dermatol."},{"key":"8062_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.17235\/reed.2020.6817\/2019","volume":"112","author":"T Pereira Guedes","year":"2020","unstructured":"Pereira Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go? Rev Esp Enferm Dig. 2020;112:580\u2013581. https:\/\/doi.org\/10.17235\/reed.2020.6817\/2019.","journal-title":"Rev Esp Enferm Dig."},{"key":"8062_CR19","doi-asserted-by":"publisher","unstructured":"Dai C, Jiang M, Sun MJ. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. The New England journal of medicine. Aug 3 2017;377:496. doi:https:\/\/doi.org\/10.1056\/NEJMc1707500","DOI":"10.1056\/NEJMc1707500"},{"key":"8062_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","volume":"20","author":"G D'Haens","year":"2022","unstructured":"D\u2019Haens G, Pan\u00e9s J, Louis E et al. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn\u2019s Disease in the CELEST Extension Study. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2022;20:2337-2346.e3. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.030.","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association."},{"key":"8062_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bjd.16798","volume":"179","author":"F Valenzuela","year":"2018","unstructured":"Valenzuela F, Korman NJ, Bissonnette R et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179:853\u2013862. https:\/\/doi.org\/10.1111\/bjd.16798.","journal-title":"Br J Dermatol."},{"key":"8062_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","volume":"88","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tsai TF, Lee MG et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci. 2017;88:36\u201345. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.05.004.","journal-title":"J Dermatol Sci."},{"key":"8062_CR23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949\u2013961. https:\/\/doi.org\/10.1111\/bjd.14018.","journal-title":"Br J Dermatol."},{"key":"8062_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PC, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet (London, England) 2015;386:552\u2013561. https:\/\/doi.org\/10.1016\/s0140-6736(14)62113-9.","journal-title":"Lancet (London, England)"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08062-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08062-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T02:04:31Z","timestamp":1695434671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08062-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["8062"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08062-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"16 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KC: No conflicts of interest. JEG: Reports advisory board roles for Eli Lilly, Almirall, Novartis, BMS, Astra-Zeneca, Boehringer Ingelheim, Sanofi, Galderma, AnaptysBio, and research grants from Almirall, Eli Lilly, Kyowa Kirin, and BMS\/Celgene. ES: No conflicts of interest. PDRH: Reports personal fees from Abbvie, personal fees from Eli Lilly, and personal fees from Pfizer, outside of the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}